Purpose: To evaluate the anti-tumor activity and tolerance of docetaxel plus vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracyclines.
Introduction
Previous treatment with anthracycline as a single agent or in combination chemotherapy is a poor prognostic factor for patients with metastatic breast cancer (MBC) undergoing second-line chemotherapy because of the subsequent low response rate. Together with anthracyclines, taxoids (paclitaxel and docetaxel) are considered to be the most active agents in the treatment of MBC. Vinorelbine (a semi-synthetic vinca alkaloid) is also one of the most active drugs for these patients [1] [2] [3] . Both taxoids and vinca alkaloids are anticancer drugs with a mechanism of action involving interaction with tubulin. Docetaxel (in vitro studies twice as potent as paclitaxel) promotes abnormal polymerization of tubulin into stable microtubule bundles by binding specifically with the beta-tubulin subunit of microtubules, thereby leading to the inhibition of microtubule depolymerization, whereas vinorelbine binds to the alpha and beta-tubulin subunits and induces depolymerization of the protein. Clinical resistance to taxoids often results from decreased stability of the tubulin complexes in tumor cells. Such cells might theoretically become very sensitive to tubulin depolimerizating agents such as vinorelbine. The reverse is true for tumor cells becoming resistant to vinca alkaloids. Thus, there might be advantages in combining taxanes with vinorelbine. Preclinical tests have supported this synergy [4, 5] , particularly the studies conducted by Bissery and colleagues [6] . These revealed enhanced activity of docetaxel plus vinorelbine (but not with other vinca alkaloids) in the MA 16/C mammary adenocarcinoma model when both agents were administered simultaneously or 24 hours apart at 80% of the highest nontoxic dose. Docetaxel and vinorelbine combinations have been widely investigated in non-smallcell lung cancer patients, whereas few phase I and II trials have been reported for MBC patients [9] [10] [11] [12] [13] [14] [15] [16] [17] . Therefore, we conducted a study aimed to evaluate the combination of docetaxel plus vinorelbine both on day 1, every 21 days, in MBC patients with prior exposure to anthracyclines.
Patients and methods Results

Patients
From November 1996 to August 2000 all eligible patients presenting with disease at our Institution were considered for the study. Eligibility criteria for female patients included histologically proven breast cancer and metastatic disease, having failed at least one regimen of anthracycline-containing chemotherapy (adriamycin, epirubicin or mitoxantrone), either as adjuvant (disease-free interval < 12 months) or metastatic treatment Bidimensionally measurable or evaluable disease detectable by radiologic examination or physical examination in at least one lesion was required. Non-measurable disease such as pleural effusion or ascites was not allowed as the only evidence of disease. Additional eligibility criteria included age greater than 18 years. ECOG performance status 0-2. life expectancy longer than three months, more than three weeks since past treatment, neutrophil count >1500/mm 3 . platelets > 100.000/mnr 1 , hemoglobin >9g/dl, creatinine <2 mg/dl. total bilirrubin <l.3 mg/dl and ventricular ejection fraction >40%. Only for loxicity evaluation purposes, were MBC patients with medical contraindication for anthracyclines also offered the study. Exclusion criteria were prior exposure to docetaxel or vinorelbine, pregnancy or lactation, history of prior malignacy except for adequately treated nonmelanomatous skin carcinoma or cervical carcinoma in situ, pre-existing peripheral neuropathy (PN). brain mctastases or meningeal carcinomatosis. Prior paclitaxel or high-dose chemotherapy (HDCT) with stem cell rescue were not exclusion criteria. Written informed consent was obtained from all patients.
Patient characteristics
A total of 56 patients were enrolled onto this study. Six patients with MBC and medical contraindication for anthracyclines, were only evaluable for toxicity.
The characteristics of the 50 patients with MBC and prior exposure to anthracyclines are listed in Table 1 . Fourty-six patients had been treated with adriamycin or epirubicin and four with mitoxantrone. Anthracyclines were administered as adjuvant treatment in 16 patients (32%), for metastatic disease in 24 (48%) and for both in 10 (20%); 9 patients (18%) had prior paclitaxel treatment and 25 (50%) had prior high-dose chemotherapy with stem cell rescue. Thirty-seven patients (74%) had received at least one prior chemotherapy regimen for metastatic disease and 41 (82%) had at least one prior hormonal therapy. Thirty patients (60%) had multiple metastatic sites. Liver and lung disease were the predominant metastatic sites in 31 patients (62%). Median number of courses given per patient was six (range 1-6).
Mean delivered dose intensity received by the patients Treatment
This study initially evaluated intravenous infusion of docetaxel (75 mg/m 2 ) over one hour followed by a rapid intravenous infusion of vinorelbine (30 mg/m 2 ). both on day I, repeated every three weeks. However. 8 of the first 13 patients developed neutropenic fever, including one toxic death, which prompted a dose reduction of 20% for both drugs All subsequent patients were treated with 60 mg/m 2 of docetaxel plus 24 mg/m 2 vinorelbine every three weeks up to progression or six courses. Oral dexamethasone 6 mg b.i.d. was given on days 0 to 3. and dexamethasone 20 mg. ranitidine 150 mg, diphenhydramine 25 mg and granisetron 3 mg were infused intravenously 30 minutes prior to docetaxel as premedication. Treatment was repeated every three weeks provided that the patient had a neutrophil count of > 1500/ml and a platelet count > 100,000/ml. In case of persistent myelosuppression (as measured on day 21), treatment was deferred until bone marrow recovery The doses of docetaxel and vinorelbine were to be reduced by 20% over the remaining courses in patients with neutropenic fever. No prophylactic administration of colony-stimulating factors was allowed.
The first objective of this phase II trial was to determine the response rate of docetaxel and vinorelbine in patients with advanced breast carcinoma and prior exposure to anlhracyclines and/or anthracenediones, and the toxicity rate of this regimen. Using a one-sided test for differences, efficacy was calculated with two steps in 35 patients planned for enrollment (a, 5%; p\ 20%). The '0' hypothesis was that there is an ineffective chemotherapy protocol if the response rate is 20% or less, and it is considered effective if the rate is 40% or higher Patients received at least three courses of docetaxel plus vinorelbine before response was evaluated, except for those who had overt progression of the disease after the first or second course of treatment. Response was graded using standard criteria [7] . Duration of response was calculated as the time from first docetaxel and vinorelbine infusion to first objective evidence of tumor progression. Response duration and time to progression were calculated by the Kaplan-Meier method. Toxicity was graded according to the NCI Common Toxicity Criteria [8] , Because of the potential for neurotoxicity, patients were evaluated for PN before treatment and after three and six courses, with complete neurological examination, electroneurography, electromiography and somatosensonal evoked potentials. 
Response
Forty-nine patients who completed at least one cycle of treatment were assessable for response. One 66-year-old patient was not assessable for response as she died from non-neutropenic pneumonia on day eleven after first course.
In an intention-to-treat analysis complete responses occurred in 4 patients and partial responses in 19 (overall response rate: 46%; 95% CI: 32%-60%); 14 patients (28%) had stable disease and 12 (24%) had disease progression on therapy. Responses were observed in all sites. Three complete responses occurred in patients with non-visceral metastases, and one in a patient with liver metastasis that had previously achieved a complete response to anthracyclines and HDCT. Among the group of 25 patients previously treated with HDCT with stem cell rescue there were 11 responders (44%); three complete responses, eight partial responses, eight stable diseases and six progressions were noted. The response rate among patients with anthracycline resistance (relapse or progression before a doxorubicin-or epirubicin-free interval of six months) was 45% (5 of 11 patients). All these were partial responses. Thirty-three patients have expired to date. Median follow-up for the surviving patients was 73 weeks (range 20-129). By the KaplanMeier method median time to disease progression was 21 weeks, and median duration of response 29 weeks. Figure 1 demonstrates survival. Median survival time was 47 weeks (95% CI: 25 to 69 weeks).
Toxicity
A total of 252 cycles of docetaxel and vinorelbine were administered to the 56 patients enrolled in this trial. The safety profile of the docetaxel plus vinorelbine combination is listed in Table 2 .
Neutropenic fever and mucositis were the dose-limiting toxicities of this combination. With the original planned dose of docetaxel 75 mg/m 2 and vinorelbine 30 mg/m 2 8 of 13 patients had neutropenic fever and five had grade 3-4 mucositis. Even though neutropenia was of short duration, a 70-year-old patient with medical contraindication for anthracyclines died with sepsis. At the reduced doses of docetaxel 60 mg/m 2 plus vinorelbine 24 mg/m 2 only 15 (7%) of the 200 courses given were complicated by neutropenic fever and 6 (3%) by grade 3-4 mucositis. Since no nadir of CBC counts were routinely performed, the values recorded correspond mainly to those seen on day 21 of each cycle. Myelosuppression was mild and limited mainly to the oldest patients (>70 years) and patients with prior extensive chemotherapy, especially HDCT. Grade 3 or 4 neutropenia were observed in five (9%) and fourteen (25%) of 56 patients. Grade 3^4 anemia occurred in five (9%) patients. No major thrombocytopenia was seen. Two patients had grade 3 nausea or vomiting. Two patients had grade 3 diarrea. Moderate fluid retention occurred in four patients and these responded to diuretics. One patient had important asthenia and another had a cutaneous herpes zoster infection after her sixth cycle.
As for peripheral neurotoxicity (PN), no grade 3-4 PN was noted. After three courses of treatment mild grade 1 sensory PN (absent tendon reflexes) occurred in 90% of patients, but only 31% had distal paresthesias in the feet. After 6 courses PN was grade 2 (objective sensory loss in feet) in 55% of patients and grade 1 in the remaining patients. All patients became asymptomatic within two months after treatment completion. Neurophysiological assessment after three courses showed only decreased amplitude of sensitive evoked potentials in 54% of patients. And after six courses, sensory axonal changes were noted in 77% of patients and decreased peroneal motor amplitude in 44% of patients.
Discussion
Our study shows that the combination of docetaxel 60 mg/m 2 and vinorelbine 24 mg/m 2 given on day 1 every three weeks is active and well tolerated in MBC patients who had prior exposure to anthracyclines. This regimen was designed with a clear palliative aim as 74% Abbreviations, n -number of patients; G-CSF -allowed or not; CT -percentage of patients with prior chemotherapy for M BC; A -percentage of patients with prior anthracyclines therapy; RR -overall response rate; d -day; w -weeks; NA -no data available; PS -present study.
of patients had received at least one prior regimen for metastatic disease and 50% underwent HDCT for adjuvant or metastatic disease. This schedule tried to provide a reasonable chance of symptom improvement while attempting to minimize impairment of the quality of life. At the same time we wanted to offer the patients a regimen that is convenient and cost-effective in terms of number of visits and duration of stay in an out-patient setting.
In the phase I trial conducted by Fumoleau et al. [9, 17] the recommended dose for phase II studies was docetaxel 85 mg/m 2 day I and vinorelbine 20 mg/m day 1 and 5 every 3 weeks; dose-limiting toxicity was febrile neutropenia and grade 4 mucositis. Responses were observed at all dose levels and in all disease sites, with an overall response rate of 67%. A recent weekly docetaxel plus vinorelbine dose-finding study [16] reports that docetaxel 35 mg/m 2 plus vinorelbine 25 mg/m 2 , both on day 1 and 8 of a 3-week course, in refractory advanced breast cancer is safe. Based on preclinical activity of simultaneous administration of both drugs, and with the aim to test a single-day course schedule without colony-stimulating factors, and taking into account the possibility of inducing severe peripheral neuropathy and/or high rates of neutropenic fever events, we selected a relatively low-dose treatment with docetaxel 75 mg/m 2 and vinorelbine 30 mg/m 2 . However, this initial schedule was not feasible because of doselimiting toxicity that prompted a dose reduction for both drugs.
Neutropenia was a prominent toxicity, although it was mild and limited mainly to older and heavily pretreated patients, as has been reported in most docetaxel plus vinorelbine combination studies. In all cases the hematologic toxicity was reversible. Neutropenic fever occurred only in 7% of courses, a low rate as corresponds to a lower dose of docetaxel in comparison to other schedules, although in some of them G-CSF support was needed to allow therapy. Those studies report a range of neutropenic fever of 8%-18% [10] [11] [12] [13] . Other hematological toxicities in our study were easily manageable.
Nonhematologic toxicity was also not troublesome in the majority of patients and did not cause any omission of treatment. Fluid retention related with docetaxel responded to diuretics in all cases. Synergistic neurotoxicity of docetaxel when combined with vinorelbine has been more of a theoretical concern than a clinical problem, even though neurophysiologic monitoring of asymptomatic patients was performed in this study. PN was a cumulative toxicity but did not reach a grade 3 in any patient after six courses of treatment. Paresthesias were treated with gabapentin until symptoms resolved, which occurred in all cases within two months of completion of treatment. Neuropathy may be especially relevant in patients with pre-existing grade 1 neuropathy as a consequence of previous neurotoxic chemotherapy such as cisplatin or paclitaxel, and some neurological tests may be recommended to patients who are to undergo docetaxel or vinorelbine-based chemotherapy in this setting [20] . Table 3 shows the results of phase II studies reported to date with different docetaxel plus vinorelbine schedules. The treatment we have tested has an overall response rate of 46%, which is consistent with other docetaxel plus vinorelbine combinations reported in MBC patients with prior exposure to anthracyclines (range: 37%-59%) [10, 11, 13, 15] , and with results observed with combinations of paclitaxel plus vinorelbine in this setting (range: 39%-57%) [18] . Of course, many of the patients we enrolled for this study had an anthracyclinefree interval too long to be considered strictly resistant, but a surprising high rate of activity was observed in the analysis of patients with an early (<6 months) relapse or progression during or after an epirubicin-or doxorubicin-containing regimen. Nevertheless, response rates in strictly anthracycline-resistant MBC patients with single drugs have been reported as follows: docetaxel (100 mg/m 2 ) 32%-57%, paclitaxel 6%-30% and vinorelbine 16% [19] . In patients with prior HDCT the combination also seems to be very active. Thus there might be a partial lack of cross-resistance between docetaxel plus vinorelbine and anthracyclines.
The excellent tolerance and acceptable quality of life for this schedule may allow more than six courses to be given in responding patients. Median time to disease progression and duration of response might be improved in these heavily pretreated patients by giving this treatment up to progression or unacceptable toxicity.
Combinations of vinorelbine plus taxanes are attractive combinations for MBC patients in view of the single-drug activity of these drugs in this disease, and also because of the fact of the increasing number of patients with MBC that have already received anthracyclines as adjuvant treatment. Docetaxel-vinorelbine combinations have demonstrated excellent activity and safety and could be used as a first-line therapy in patients who cannot receive further anthracycline treatment, or as a second-line combination after anthracycline treatment has failed. Results from ongoing multicenter phase II trials are awaited with interest. The high response rate of the schedule we have tested, especially in patients resistant to anthracyclines, has encouraged us to design a study with docetaxel plus vinorelbine as adjuvant treatment in patients not responding to anthracyclinebased neoadjuvant chemotherapy.
